Viruses like SARS-CoV-2 use sugar molecules to hide from the immune system, but scientists at Scripps Research have designed ...

Researchers from Abl Bio Inc. have published preclinical data for ABL-112, an Fc-competent bispecific antibody (BsAb) targeting TIGIT and 4-1BB (TIGIT x 4-1BB), being developed for the treatment of ...

On March 13, 2025, the US Court of Appeals for the Federal Circuit (Federal Circuit) issued a decision titled In Re: Xencor, Inc. (the ...

Leinco Technologies offers high-purity research-grade biosimilar antibodies with the same specifications as many therapeutic antibodies. Therapeutic antibodies are widely used for the treatment of ...

GLP-1 receptor agonists are peptide-based drugs used for managing diabetes and for weight loss, but these treatments have had shortages recently. Now, through a process called in vivo antibody ...

Oncogene permanent activation in a single targeted cell of zebrafish together with a reprogramming factor transient activation is sufficient to induce the malignant transformation of the cell and ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced participation in the ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...